Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1934270 | 1.00 | CYP2D6 (0.41) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL975517 | 1.00 | CYP2D6 (0.41) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL22398615 | 0.98 | CYP2D6 (0.40) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL853594 | 0.98 | CYP2D6 (0.40) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL16754608 | 0.98 | CYP2D6 (0.40) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| Ammonia Solution, Strong SCHEMBL2393369 | 0.98 | CYP2D6 (0.40) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| Hydrochloric Acid SCHEMBL918665 | 0.98 | CYP2D6 (0.40) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL4426559 | 0.88 | CA12 (0.38) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL852345 | 0.88 | CYP2D6 (0.42) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL2363538 | 0.88 | CYP2D6 (0.42) | CYP2D6HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478081-B2 | Application of aspartic acid derivative in preparing animal feed additive | Anipha Technologies Pty Ltd (AU) | 2025-11-25 | — | — | US | disclosed |
| EP-4626489-A1 | PCTA DERIVATIVES, CONJUGATES THEREOF AND USES THEREOF | Novartis AG (CH) | 2025-10-08 | — | — | EP | disclosed |
| US-12302927-B2 | Application of aspartic acid derivative in preparing animal feed additive | Anipha Technologies Pty Ltd (AU) | 2025-05-20 | — | — | US | disclosed |
| US-20240284937-A1 | APPLICATION OF ASPARTIC ACID DERIVATIVE IN PREPARING ANIMAL FEED ADDITIVE | Anipha Technologies Pty Ltd (AU) | 2024-08-29 | — | — | US | disclosed |
| WO-2024116053-A1 | PCTA DERIVATIVES, CONJUGATES THEREOF AND USES THEREOF | NOVARTIS AG (CH) | 2024-06-06 | — | — | WO | disclosed |
| US-10654834-B2 | Non-systemic TGR5 agonists | Venenum Biodesign, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190330191-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | Venenum Biodesign, LLC (US) | 2019-10-31 | — | — | US | disclosed |
| WO-2017063755-A1 | CONFORMATIONALLY CONSTRAINED MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017063754-A1 | CONFORMATIONALLY CONSTRAINED MACROCYCLIC COMPOUNDS AS PIN1 MODULATORS | POLYPHOR AG (CH) | 2017-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12478081-B2 | Application of aspartic acid derivative in preparing animal feed additive | AADAT, SLC1A5, SLC1A3 | CYP2D6 4385/4885HDAC3 2280/4885HDAC1 2201/4885 |
| US-20190330191-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | GPR119, FFAR1, FFAR3 | CYP2D6 1941/4885HDAC3 1799/4885HDAC1 2484/4885 |
| US-12302927-B2 | Application of aspartic acid derivative in preparing animal feed additive | AADAT, SLC1A5, SLC1A3 | CYP2D6 4062/4885HDAC3 2225/4885HDAC1 2235/4885 |
| US-10654834-B2 | Non-systemic TGR5 agonists | GPR119, SSTR5, FFAR3 | CYP2D6 1857/4885HDAC3 1794/4885HDAC1 2508/4885 |
| US-20240284937-A1 | APPLICATION OF ASPARTIC ACID DERIVATIVE IN PREPARING ANIMAL FEED ADDITIVE | AADAT, SLC1A5, SLC1A3 | CYP2D6 4385/4885HDAC3 2280/4885HDAC1 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.